U.S. FDA Still Allows Ranbaxy Drugs To Be Imported Under Cloud
This article was originally published in PharmAsia News
Even as the U.S. FDA gathers evidence against India's Ranbaxy Laboratories for allegedly adulterated drugs, the drug maker's products continue to flow into the United States. Already this year, Ranbaxy won marketing rights from the FDA for 11 more drugs. Critics of the FDA and the U.S. Customs Service complain the government is doing little to stop Ranbaxy products from entering the United States, a normal response when an importer is accused of bringing in adulterated and misbranded drugs. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.